Medidur trial completes enrolment

Article

Alimera Sciences and pSivida have completed enrolment for the FAME (Fluocinolone Acetonide in diabetic Macular Edema) study of Medidur.

Alimera Sciences and pSivida have completed enrolment for the FAME (Fluocinolone Acetonide in diabetic Macular Edema) study of Medidur.

FAME is a double-masked, randomized, multicentre study that has now enrolled 900 patients across the US, Canada, Europe and India and will assess the safety and efficacy of Medidur for the treatment of diabetic macular oedema (DME).

An independent Data Safety Monitoring Board (DSMB) has recently recommended that the pivotal Phase III clinical trial continue under the current protocol, without change.

Medidur is a tiny, injectable insert that delivers fluocinolone acetonide, a corticosteroid, to the retina for up to three years.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.